Trials / Completed
CompletedNCT00693667
Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women
A Phase II, Double-Blind, Randomized, Placebo-controlled, Clinical Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- PhytoHealth Corporation · Industry
- Sex
- Female
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for the prevention of osteoporosis. The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PH3 | Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2008-06-09
- Last updated
- 2021-04-01
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00693667. Inclusion in this directory is not an endorsement.